米卡芬金
真菌血症
达托霉素
医学
菌血症
加药
棘白菌素
重症监护医学
光滑假丝酵母
外科
内科学
抗生素
抗真菌
万古霉素
真菌病
微生物学
伏立康唑
细菌
金黄色葡萄球菌
生物
氟康唑
遗传学
皮肤病科
作者
M. Gabriela Cabanilla,Nicholas Villalobos
摘要
Studies have demonstrated that ECMO leads to pharmacokinetic changes, with alterations in volume of distribution, clearance and drug sequestration by the circuit. We describe a successful dosing approach for daptomycin and micafungin for the treatment of VRE faecium bacteremia and C. glabrata fungemia in a patient receiving veno-venous ECMO and CRRT.We report a case of a patient with ARDS on veno-venous ECMO complicated by VRE faecium bacteremia and C. glabrata fungemia. The patient was treated with daptomycin 10 mg/kg every 24 h and micafungin 150 mg every 24 h for 14 days. Key observations included the documented bacteremia and fungemia clearance without the need for ECMO circuit exchange.This case report demonstrates successful bacteremia and fungemia clearance in an adult without the need for ECMO circuit exchange. It also highlights the need for more research to identify optimal antimicrobial dosing strategies in similar scenarios.
科研通智能强力驱动
Strongly Powered by AbleSci AI